The stream · Daily digest
The stream: Friday, November 6, 2026
11 briefs from ClinicalTrials.gov, FDA and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 5
-
United Therapeutics registers SUMMIT OLE study
The study, titled An Open-label Extension Study of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD), plans to enroll 400 participants and is expected to start in March 2027. It is a Phase 2 and Phase 3 open-label extension aimed at evaluating long-term safety and efficacy.
Source: ClinicalTrials.gov registry record, November 6, 2026
-
AstraZeneca registers Phase III trial of AZD6234 in obesity and type 2 diabetes
The SELENE-Asia study plans to enroll 330 participants and begin recruiting on January 4, 2027. It will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.
Source: ClinicalTrials.gov registry record, November 6, 2026
-
Sanofi registers Phase 2 and 3 study of rilzabrutinib in iCVID
The study, first posted on ClinicalTrials.gov on November 6, 2026, plans to enroll 96 participants and has a planned start date of November 9, 2026. It evaluates efficacy, safety, and tolerability of rilzabrutinib in adults with inflammatory common variable immunodeficiency over four parts, with a planned primary completion date of May 10, 2035.
Source: ClinicalTrials.gov registry record, November 6, 2026
-
Jiangsu HengRui registers Phase 3 trial of SHR-3167 vs insulin glargine
The study plans to enroll 450 insulin-naive type 2 diabetes participants to compare once-weekly SHR-3167 with once-daily insulin glargine. It is planned to start in November 2026 and complete primary outcomes in October 2027.
Source: ClinicalTrials.gov registry record, November 6, 2026
-
GlaxoSmithKline posts results of Phase 3b study of rMenB+OMV NZ in adolescents
Results for the Phase 3b, open-label study of the meningococcal group B vaccine rMenB+OMV NZ were first posted on ClinicalTrials.gov on November 6, 2026, after enrolling 312 participants. The study evaluated the immune response and safety of a booster dose in healthy 10- to 20-year-old participants who were primed with the vaccine during infancy.
Source: ClinicalTrials.gov results record, November 6, 2026
Approvals · 3
-
FDA approves pembrolizumab or Keytruda Qlex for TMB-H solid tumors
On October 16, 2026, the FDA granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors defined as ≥13 mutations/megabase. The approval converts the prior accelerated approval and amends the TMB-H definition to ≥13 mut/Mb, as efficacy was not confirmed in patients with TMB of 10 to <13 mut/Mb.
Source: FDA approval notification, November 6, 2026
-
FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer
On October 8, 2026, the FDA approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The approval also covers Tecentriq Hybreza for patients 12 years of age and older who weigh 40 kg or greater.
Source: FDA approval notification, November 6, 2026
-
FDA approves RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval to RYBREVANT FASPRO, a co-formulated amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.
Source: Company press release (PR Newswire), November 6, 2026
Policy · 2
-
Halozyme says royalty revenue should remain minimal through 2035 under new CMS rule
Halozyme projects zero to minimal impact to its royalty revenues through at least 2035 based on its analysis of CMS's final rule for the Medicare Drug Price Negotiation Program issued November 5, 2026. The company also says the rule does not affect its ability to enter new ENHANZE partnership agreements.
Source: Company press release (PR Newswire), November 6, 2026
-
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
The agreement lets eligible patients receive prescriptions for Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers platform at self-pay prices of $299 and $149 per month, respectively. Patients can complete a consultation, receive a prescription, and have the medication shipped directly to their home.
Source: Company press release (PR Newswire), November 6, 2026
Regulation · 1
-
FDA classifies external mechanical stimulator for congestion as class II
A final order has been issued to place the device for relieving congestion into category II, adding special controls. The action is intended to provide reasonable assurance of safety and effectiveness and to enhance patients' access to innovative devices by reducing regulatory burdens.
Source: Federal Register rule, November 6, 2026